Headline
The latest stories from AHA Today.
The Department of Health and Human Services’ Health Sector Cybersecurity Coordination Center (HC3) issued a monthly bulletin that consolidates a wide range of cyber security alerts from across government on the latest cybersecurity trends and threats, including guidance on hardening remote access…
The Centers for Disease Control and Prevention updated the list of underlying medical conditions that put adults of any age at higher risk for severe COVID-19 based on the latest scientific evidence.
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective Oct. 18.
This year’s AHA Dick Davidson NOVA Award honorees from CommonSpirit Health, Luminis Health, Memorial Health System, Providence, and Texas Health Resources will discuss their award-winning programs to address homelessness, an aging population, behavioral health and substance use, lagging community…
The National Institutes of Health awarded a total of $78 million in funding to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, with the goal of bringing to market as soon as this year new home and point-of-care tests that can detect multiple respiratory infections.
States and territories can apply through April 8, 2022, for a portion of $100 million in American Rescue Plan Act funding to help repay educational loans for primary care clinicians in exchange for service in underserved communities, the Health Resources and Services Administration announced.
A coalition of hospital and physician organizations, including the AHA, urged the Centers for Medicare & Medicaid Services to give Medicare accountable care organizations the option to use pre-pandemic spending benchmarks to set financial targets beginning in performance year 2022.
Abbott Molecular Inc. issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and Aug. 31, 2021, for their potential to give false positive results.
The Centers for Disease Control and Prevention released an operational planning guide for pediatric COVID-19 vaccination and preliminary information on the pediatric Pfizer COVID-19 vaccine.
Available data support the safety and effectiveness of the Johnson & Johnson COVID-19 vaccine for emergency use authorization as a booster dose in individuals aged 18 and older at least two months after an initial single dose, the Food and Drug Administration’s Vaccines and Related Biological…